Clinical trial
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
NCT00002208
Study timeline
Registry last updated2005-06-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HIV Infectionsunresolved
Interventions
LamivudineDRUG · verified · RxNorm: lamivudine
StavudineDRUG · verified · RxNorm: stavudine
ZidovudineDRUG · verified · RxNorm: zidovudine
Sponsors & collaborators
Merck Sharp & Dohme LLClead sponsor
Mapped research locations
ChicagoIllinois, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1PittsburghPennsylvania, United States1BirminghamAlabama, United States1Washington D.C.District of Columbia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00002208 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.